Abivax

Immunology (clinical-stage biotech)

ABVX · Nasdaq · France

Share price · ABVX

$83.83-35.11 (-29.52%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.2M (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ABVX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Sep 2026+6.4%
  2. 30 Jun 2026+38.6%
  3. 4 Jun 2026+16.4%
  4. 3 Jun 2026+24.3%
  5. 2 Jun 2026-44.1%
  6. 30 Apr 2026+10.5%

    Nothing announced by ABVX that day or the session before.

  7. 13 Apr 2026-3.8%
  8. 22 Dec 2025+20.7%
  9. 9 Dec 2025+6.9%

    Nothing announced by ABVX that day or the session before.

  10. 20 Nov 2025+8.8%

    Nothing announced by ABVX that day or the session before.

Share of unusual movement by asset

For each asset, the share of ABVX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
obefazimod
events and moves
7shown from 8 days
Assets with fewer than 8 event days, together—98%
Other company news (earnings, financing, releases naming no asset)—0%
Sessions with no dated event—2%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
miR-124Small molecule
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
obefazimodPhase 2Moderately to Severely Active Crohn Disease
Est. primary completion 2026-12 · NCT06456593 · CT.gov ↗
What to watch
2026-09-30 Financial ReportEarnings report
Expected report date 2026-12-21 · Fiscal period ending 2026-09-30
What to watch
2028 (1)
March 2028 (1)
obefazimodPhase 2Ulcerative Colitis
Est. primary completion 2028-03 · NCT05177835 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 June 2026Topline resultobefazimodPhase 3 ABTECT maintenance trial of obefazimod met the primary endpoint (clinical remission at Week 44); NDA planned for late Q4 2026
Abivax · Source ↗
22 July 2025Topline resultobefazimodPhase 3 ABTECT-1 and ABTECT-2 induction trials of obefazimod met the primary endpoint (clinical remission at Week 8, 50 mg)
Abivax · Source ↗

Financial reports

Quarterly & interim (9)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-H1—$126M$443M+ $16M short-term inv.$97Mreport ↗
View 8 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$56M$559M$64Mreport ↗
2025-Q3—$65M$692M+ $0 short-term inv.$179M-$83M operating cash flowreport ↗
2025-H1—$85M$71M$36Mreport ↗
2025-Q2—$44M$71M+ $0 short-term inv.$55M-$38M operating cash flowreport ↗
2025-Q1—$41M$112M+ $0 short-term inv.$55M-$35M operating cash flowreport ↗
2024-Q3—$48M$202M$61M-$39M operating cash flowreport ↗
2024-Q2—$31M$238M$42M-$54M operating cash flowreport ↗
2024-Q1—$39M$261M$47M-$38M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$202M$607M+ $0 short-term inv.$95M-$183M operating cash flowreport ↗

Abivax reported no revenue for 2025, with neither current nor prior-year revenue disclosed. R&D spend was $201.5M, up 27.1% YoY, cash and equivalents were $607.44M, and the company reported a net loss of $380.98M, with a quarterly net burn of $380.98M.

The company expects a cash runway into Q4 2027 and remains on track to report ABTECT-UC maintenance topline results in late Q2 2026, with Phase 2b Crohn’s disease induction results and an obefazimod NDA submission in UC both expected in Q4 2026, subject to positive data. A DSMB review on March 18, 2026 found no new safety signals, with nearly 90% of participants having completed the 44-week treatment period. Key developments included senior leadership appointments, including a new Chief Commercial Officer, and the planned AGM on May 11, 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$159M$150M$42Mreport ↗
2023-FY—$112M$279M$26Mreport ↗
2022-FY——$29M—report ↗
2021-FY——$69M—report ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 251 reporting institutions held 50.3M shares ($5.4B, 57.7% of shares outstanding).

#InstitutionSharesValue
1TCG Crossover Management, LLC6,481,085$721.7M
2UBS Group AG4,547,406$506.4M
3Darwin Global Management, Ltd.3,468,657$352.1M
4MORGAN STANLEY1,704,958$189.8M
5Vestal Point Capital, LP1,500,000$167.0M
6Caligan Partners LP1,461,924$162.8M
7ADAR1 Capital Management, LLC1,394,019$155.2M
8WESTFIELD CAPITAL MANAGEMENT CO LP1,322,938$147.3M
9FMR LLC1,286,373$143.2M
10Helikon Investments Ltd1,013,324$112.8M
11Eversept Partners, LP934,423$104.0M
12JANUS HENDERSON GROUP PLC878,829$98.0M
13BAKER BROS. ADVISORS LP875,796$97.5M
14Paradigm Biocapital Advisors LP772,473$86.0M
15Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.765,915$85.3M